A Phase 3 interventional study of MenACYW conjugate vaccine and Meningococcal group A, C, W-135, and Y conjugate vaccine in Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 33 sites in 7 countries. Open to participants aged 42 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-03.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.
Among the 57 studies in Meningococcal Infections by Sanofi, this one is the 6th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2018, is one of 25 in phase 3, and was the 47th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 2 mo–23 mo · Healthy volunteers
Sanofi Pasteur, a Sanofi Company · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 42 Days to 89 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 25 · Phase 4 8
First in 2002; this study’s year is marked. 7 started in 2018.
This study's enrollment of 1,660 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 378 across the 51 interventional studies, 440 across the 6 observational. Of the 55 that completed or were terminated, 51 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Meningococcal Infections by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary objective:
This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b [DTaP-IPV-HB-Hib vaccine]) to infants and toddlers 6 weeks to 18 months old
Secondary objectives:
This study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 doses of meningococcal polysaccharide (serogroups A, C, Y and W) tetanus toxoid \[MenACYW conjugate vaccine\] 0.5 milliliter (mL) as an intramuscular (IM) injection at dose 1: 2 months of age (MoA), dose 2: 4 MoA, and dose 3: 12 to 18 MoA along with routine pediatric vaccines. The routine pediatric vaccines: hexavalent vaccine (combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and haemophilus influenzae type b conjugate vaccine \[DTaP-IPV-HB-Hib\], the pneumococcal vaccine (pneumococcal conjugate vaccine \[10-valent, adsorbed\] {PCV10} were administered in a 2+1 regimen (ie, 2 doses in infancy \[first between 6 and 12 weeks of age and second between 4 to 5 MoA\] and 1 final dose in the second year of life \[12 to 18 MoA\]); and the measles, mumps, rubella (MMR) vaccine was administered at 12 to 18 MoA.
Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV-HB-Hib vaccine · Biological: Pneumococcal vaccine (10-valent) · Biological: MMR vaccine
Participants received 3 doses of Nimenrix® 0.5 mL as an IM injection at dose 1: 2 MoA, dose 2: 4 MoA, and dose 3: 12 to 18 MoA along with routine pediatric vaccines. The routine pediatric vaccines: hexavalent vaccine (DTaP-IPV-HB-Hib), the PCV10 were administered in a 2+1 regimen (ie, 2 doses in infancy \[first between 6 and 12 weeks of age and second between 4 to 5 MoA\] and 1 final dose in the second year of life \[12 to 18 MoA\]); and the MMR vaccine was administered at 12 to 18 MoA.
Biological: Meningococcal group A, C, W-135, and Y conjugate vaccine · Biological: DTaP-IPV-HB-Hib vaccine · Biological: Pneumococcal vaccine (10-valent) · Biological: MMR vaccine
Participants received 3 doses of MenACYW conjugate vaccine 0.5 mL as an IM injection at dose 1: 2 MoA, dose 2: 4 MoA, and dose 3: 12 to 18 MoA along with routine pediatric vaccines. The routine pediatric vaccines: hexavalent vaccine (DTaP-IPV-HB-Hib), the pneumococcal conjugate vaccine (13-valent, adsorbed) \[PCV13\] were administered in a 2+1 regimen (ie, 2 doses in infancy \[first between 6 and 12 weeks of age and second between 4 to 5 MoA\] and 1 final dose in the second year of life \[12 to 18 MoA\]); and the MMR vaccine was administered at 12 to 18 MoA.
Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV-HB-Hib vaccine · Biological: Pneumococcal vaccine (13-valent) · Biological: MMR vaccine
Participants received 4 doses of MenACYW conjugate vaccine 0.5 mL as an IM injection at dose 1: 2 MoA, dose 2: 4 MoA, and dose 3: 6 MoA and dose 4: 12 to 18 MoA along with routine pediatric vaccines. The routine pediatric vaccines: hexavalent vaccine (DTaP-IPV-HB-Hib), the PCV13 were administered in a 2+1 regimen (concomitantly with the first and second doses in infancy \[first between 6 and 12 weeks of age and second between 4 to 5 MoA\] and the toddler dose of MenACYW conjugate vaccine \[12 to 18 MoA\]); and the MMR vaccine was administered at 12 to 18 MoA. The third dose of MenACYW conjugate vaccine was administered alone, without any other routine pediatric vaccines.
Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV-HB-Hib vaccine · Biological: Pneumococcal vaccine (13-valent) · Biological: MMR vaccine
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
Also known as: MenQuadfi®
Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
Also known as: Nimenrix®
Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
Also known as: Hexyon®/Hexacima®
Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
Also known as: Prevenar 13®
Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
Also known as: Synflorix®
Measles, mumps, and rubella vaccine
Also known as: M-M-RVAXPRO®
Groups 1 and 2: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the serum bactericidal assay using human complement (hSBA).
Time frame: At 30 days post Dose 3 [12 to 18 months of age (MoA)]
Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
Time frame: At 30 days post Dose 2 (4 MoA)
Groups 3 and 4: Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, W, and Y
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA.
Time frame: Group 3: Day 0 before Dose 1 (2 MoA) and Dose 3 (12 to 18 MoA) and Day 30 Post Dose 2 (4 MoA) and Dose 3 (12 to 18 MoA); Group 4: Day 0 before Dose 1 (2 MoA) and Dose 4 (12 to 18 MoA) and Day 30 Post Dose 3 (6 MoA) and Dose 4 (12 to 18 MoA)
Groups 1 and 2: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:4 and >=1:8
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
Time frame: Day 0 Before Dose 1 (2 MoA) and Day 30 Post Dose 2 (4 MoA); Day 0 Before Dose 3 (12 to 18 MoA) and Day 30 Post Dose 3 (12 to 18 MoA)
Groups 3 and 4: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:4 and >=1:8
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
Time frame: Group 3: Day 0 before Dose 1 (2 MoA) and Dose 3 (12 to 18 MoA) and Day 30 Post Dose 2 (4 MoA) and Dose 3 (12 to 18 MoA); Group 4: Day 0 before Dose 1 (2 MoA) and Dose 4 (12 to 18 MoA) and Day 30 Post Dose 3 (6 MoA) and Dose 4 (12 to 18 MoA)
Groups 1 and 2: Percentage of Participants With Vaccine Seroresponse
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre vaccination titer \<1:8, the post-vaccination titer must be \>=1:16 and for a participant with a pre vaccination titer \>=1:8, the post-vaccination titer must be at least 4-fold greater than the pre vaccination titer. Percentages are rounded off to the tenth decimal place.
Time frame: Day 30 Post Doses 2 and 3 (4 MoA and 12 to 18 MoA)
Groups 3 and 4: Percentage of Participants With Vaccine Seroresponse
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre vaccination titer \<1:8, the post-vaccination titer must be \>=1:16 and for a participant with a pre vaccination titer \>=1:8, the post-vaccination titer must be at least 4-fold greater than the pre vaccination titer. Percentages are rounded off to the tenth decimal place.
Time frame: Group 3: Day 30 Post Dose 2 (4 MoA), Day 30 Post Dose 3 (12 to 18 MoA); Group 4: D30 Post Dose 3 (6 MoA), Day 30 Post Dose 4 (12 to 18 MoA)
Geometric Mean Concentrations (GMCs) of Anti-Pertussis Antibodies
GMCs of anti-pertussis antibodies (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\]) were measured by electrochemiluminescent (ECL) assay.
Time frame: Groups 1, 2 and 3: Day 0 before Dose 1 (2 MoA); Group 4: Day 0 before Dose 4 (12 to 18 MoA)
Geometric Mean Concentrations (GMCs) of Hexavalent Vaccines
GMCs of hexavalent vaccines were measured as: anti-diphtheria, anti-tetanus, anti-pertussis antibodies (PT, FHA) by ECL assay, anti-hepatitis antibodies (anti-Hepatitis B surface antigen \[HBsAg\]) by the commercially available VITROS ECi/ECiQ, anti-poliovirus types 1, 2, and 3 by neutralization assay and anti-Haemophilus influenzae type b (anti-polyribosylribitol phosphate \[PRP\]) by Farr-type radioimmunoassay (RIA).
Time frame: Groups 1, 2 and 3: Day 30 Post Doses 2 and 3 (4 MoA and 12 to 18 MoA); Day 0 Before Dose 3 (12 to 18 MoA); Group 4: Day 30 Post Dose 4 (12 to 18 MoA)
Percentage of Participants With Response Rate for Anti-Diphtheria, Anti-Tetanus, Anti-Poliovirus Types 1, 2, and 3, Anti-Haemophilus Influenzae Type b (Anti-PRP)
GMCs of anti-diphtheria, anti-tetanus, anti-poliovirus types 1, 2, and 3, anti-haemophilus influenzae type b (anti-PRP) vaccines were measured as: anti-diphtheria, anti-tetanus by ECL assay, anti-poliovirus types 1, 2, and 3 by neutralization assay and anti-Haemophilus influenzae type b (anti-PRP) by Farr-type RIA. Response rate was defined as percentage of participants who achieved: anti diphtheria and anti-tetanus antibody concentrations \>=0.01 international units (IU)/milliliter (mL), \>=0.1 IU/mL and \>=1.0 IU/mL; anti-poliovirus types 1, 2, and 3 antibody titers \>=1:8; anti-PRP antibody concentrations \>=0.15 microgram (mcg)/mL and \>=1 mcg/mL. Percentages are rounded off to the tenth decimal place.
Time frame: Groups 1, 2 and 3: Day 30 Post Doses 2 and 3 (4 MoA and 12 to 18 MoA); Day 0 Before Dose 3 (12 to 18 MoA); Group 4: Day 30 Post Dose 4 (12 to 18 MoA)
Percentage of Participants Who Achieved Vaccine Seroresponse for Anti-Pertussis Antibodies
GMCs of anti-pertussis antibodies (PT, FHA) were measured by ECL assay. The pertussis vaccine seroresponse for anti-PT and anti-FHA was defined as: For groups 1, 2, and 3, 30 days after dose 2 in infancy as if the pre-primary vaccination concentration is \<4 × lower limit of quantification (LLOQ), post-primary vaccination concentration \>=4 × LLOQ, if the pre-primary vaccination concentration is \>=4 ×LLOQ, post-primary vaccination concentration \>=pre-primary vaccination concentration; and for Groups 1, 2, and 3, before and 30 days after the dose 3 and for group 4, before and 30 days after the dose 4 as if the pre-booster vaccination concentration is \<4 × LLOQ, post-booster vaccination concentration \>=4 × pre-booster concentration, if the pre-booster vaccination concentration is \>=4 × LLOQ, post-booster vaccination concentration \>=2 × pre-booster concentration. Percentages are rounded off to the tenth decimal place.
Time frame: Groups 1, 2 and 3: Day 30 Post Doses 2 and 3 (4 MoA and 12 to 18 MoA); Group 4: Day 30 Post Dose 4 (12 to 18 MoA)
Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 and >=100 Milli-International Units (mIU)/mL
GMCs of anti-hepatitis antibodies (anti-HBsAg) was measured by the commercially available VITROS ECi/ECiQ. Response rate for anti-HBsAg was defined as percentage of participants who achieved anti-HBsAg antibody concentrations \>=10 mIU/mL and \>=100 mIU/mL. Percentages are rounded off to the tenth decimal place.
Time frame: Groups 1, 2 and 3: Day 30 Post Doses 2 and 3 (4 MoA and 12 to 18 MoA); Day 0 Before Dose 3 (12 to 18 MoA); Group 4: Day 30 Post Dose 4 (12 to 18 MoA)
Groups 1 and 2: Geometric Mean Concentrations (GMCs) of Pneumococcal Conjugate Vaccine (10-Valent, Adsorbed) (PCV10) Vaccine
GMCs of anti-pneumococcal antibodies was assessed by pneumococcal capsular polysaccharide (PnPS) Immunoglobulin G (IgG) ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) antibodies in human serum.
Time frame: At 30 days post Dose 2 (4 MoA) and Dose 3 (12 to 18 MoA)
Groups 3 and 4: Geometric Mean Concentrations (GMCs) of Pneumococcal Conjugate Vaccine (13-Valent, Adsorbed) (PCV13) Vaccine
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) antibodies in human serum.
Time frame: Group 3: At 30 days post Dose 2 (4 MoA) and Dose 3 (12 to 18 MoA); Group 4: At 30 days post Dose 4 (12 to 18 MoA)
Groups 1 and 2: Percentage of Participants With Response Rate >=0.35 mcg/mL for Pneumococcal Conjugate Vaccine (10-Valent, Adsorbed) PCV10 Vaccine
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) antibodies in human serum. Percentages are rounded off to the tenth decimal place.
Time frame: At 30 days post Dose 2 (4 MoA) and Dose 3 (12 to 18 MoA)
Groups 3 and 4: Percentage of Participants With Response Rate >=0.35 mcg/mL for Pneumococcal Conjugate Vaccine (13-Valent, Adsorbed) PCV13 Vaccine
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) antibodies in human serum. Percentages are rounded off to the tenth decimal place.
Time frame: Group 3: At 30 days post Dose 2 (4 MoA) and Dose 3 (12 to 18 MoA); Group 4: At 30 days post Dose 4 (12 to 18 MoA)
Geometric Mean Concentrations (GMCs) of Anti-Measles, Mumps and Rubella (MMR) Antibodies
GMCs of anti-measles and anti-rubella antibodies were measured by bulk IgG enzyme immunoassay (EIA) and anti-mumps antibodies were assessed by enzyme-linked immunosorbent assay (ELISA).
Time frame: Groups 1, 2 and 3: At 30 days post Dose 3 (12 to 18 MoA); Group 4: At 30 days post Dose 4 (12 to 18 MoA)
Percentage of Participants Who Achieved Vaccine Response for Measles, Mumps and Rubella (MMR) Antibodies
GMCs of anti-measles and anti-rubella antibodies were measured by bulk IgG EIA and anti-mumps antibodies were assessed by ELISA. Vaccine response against anti-measles, anti-mumps, anti-rubella antibodies were defined as percentage of participants with anti-measles, anti-mumps, anti-rubella antibody concentration that met the respective mentioned criterion: measles: \>=255 mIU/mL; mumps: \>=10 mumps antibody units/mL and rubella: \>=10 IU/mL. Percentages are rounded off to the tenth decimal place.
Time frame: Groups 1, 2 and 3: At 30 days post Dose 3 (12 to 18 MoA); Group 4: At 30 days post Dose 4 (12 to 18 MoA)
This study was conducted at 33 investigational sites in 7 countries between 14 December 2018 to 24 May 2023.
| Milestone | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| Started | 714 | 726 | 112 | 108 |
| Safety analysis set (safas) | 696 | 706 | 112 | 108 |
| Completed | 681 | 691 | 106 | 104 |
| Not completed | 33 | 35 | 6 | 4 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Protocol deviation | 5 | 7 | 3 | 0 |
| Withdrew: Withdrawal by parent/guardian | 24 | 24 | 2 | 4 |
| Withdrew: Lost to follow-up | 3 | 3 | 1 | 0 |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the serum bactericidal assay using human complement (hSBA).
| Titer | Group 1: MenACYW | Group 2: Nimenrix |
|---|---|---|
| Serogroup A | 131 (113 to 151) | 189 (165 to 218) |
| Serogroup C | 565 (505 to 632) | 120 (106 to 135) |
| Serogroup W | 423 (382 to 468) | 275 (247 to 305) |
| Serogroup Y | 285 (260 to 313) | 160 (145 to 177) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix |
|---|---|---|
| Serogroup A | 63.6 (59.2 to 67.8) | 75.8 (71.8 to 79.5) |
| Serogroup C | 98.8 (97.5 to 99.6) | 91.9 (89.3 to 94.1) |
| Serogroup W | 96.5 (94.6 to 97.9) | 94.5 (92.1 to 96.3) |
| Serogroup Y | 96.5 (94.5 to 97.9) | 93.5 (91.0 to 95.5) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA.
| Titer | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|
| PPAS1: Serogroup A: Day 0 before dose 1 | 3.00 (2.58 to 3.49) | 2.86 (2.49 to 3.28) |
| PPAS1: Serogroup A: Day 30 post dose 2 | 14.8 (10.6 to 20.8) | — |
| PPAS1: Serogroup A: Day 30 post dose 3 | — | 23.0 (17.1 to 30.9) |
| PPAS1: Serogroup C: Day 0 before dose 1 | 3.91 (3.16 to 4.84) | 3.88 (3.25 to 4.62) |
| PPAS1: Serogroup C: Day 30 post dose 2 | 309 (235 to 407) | — |
| PPAS1: Serogroup C: Day 30 post dose 3 | — | 481 (376 to 616) |
| PPAS1: Serogroup W: Day 0 before dose 1 | 2.67 (2.40 to 2.96) | 3.08 (2.63 to 3.60) |
| PPAS1: Serogroup W: Day 30 post dose 2 | 102 (79.7 to 131) | — |
| PPAS1: Serogroup W: Day 30 post dose 3 | — | 196 (156 to 245) |
| PPAS1: Serogroup Y: Day 0 before dose 1 | 2.85 (2.45 to 3.32) | 2.76 (2.36 to 3.23) |
| PPAS1: Serogroup Y: Day 30 post dose 2 | 73.4 (57.7 to 93.5) | — |
| PPAS1: Serogroup Y: Day 30 post dose 3 | — | 150 (116 to 195) |
| PPAS2: Serogroup A: Day 0 before dose 3 | 5.18 (4.22 to 6.37) | — |
| PPAS2: Serogroup A: Day 30 post dose 3 | 104 (67.9 to 161) | — |
| PPAS2: Serogroup A: Day 0 before dose 4 | — | 8.13 (6.33 to 10.4) |
| PPAS2: Serogroup A: Day 30 post dose 4 | — | 62.0 (39.9 to 96.4) |
| PPAS2: Serogroup C: Day 0 before dose 3 | 26.2 (18.7 to 36.8) | — |
| PPAS2: Serogroup C: Day 30 post dose 3 | 819 (622 to 1078) | — |
| PPAS2: Serogroup C: Day 0 before dose 4 | — | 56.9 (42.4 to 76.4) |
| PPAS2: Serogroup C: Day 30 post dose 4 | — | 791 (608 to 1029) |
| PPAS2: Serogroup W: Day 0 before dose 3 | 39.1 (29.6 to 51.8) | — |
| PPAS2: Serogroup W: Day 30 post dose 3 | 1049 (782 to 1406) | — |
| PPAS2: Serogroup W: Day 0 before dose 4 | — | 92.6 (74.3 to 115) |
| PPAS2: Serogroup W: Day 30 post dose 4 | — | 1024 (806 to 1301) |
| PPAS2: Serogroup Y: Day 0 before dose 3 | 33.0 (25.0 to 43.5) | — |
| PPAS2: Serogroup Y: Day 30 post dose 3 | 589 (470 to 737) | — |
| PPAS2: Serogroup Y: Day 0 before dose 4 | — | 85.8 (68.2 to 108) |
| PPAS2: Serogroup Y: Day 30 post dose 4 | — | 632 (512 to 780) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix |
|---|---|---|
| PPAS1: Serogroup A: >=1:4: Day 0 before dose 1 | 31.1 (27.1 to 35.3) | 28.3 (24.5 to 32.4) |
| PPAS1: Serogroup A: >=1:8: Day 0 before dose 1 | 5.6 (3.8 to 7.9) | 6.4 (4.4 to 8.8) |
| PPAS1: Serogroup A: >=1:4: Day 30 post dose 2 | 77.2 (73.3 to 80.7) | 88.0 (84.8 to 90.7) |
| PPAS1: Serogroup A: >=1:8: Day 30 post dose 2 | 63.6 (59.2 to 67.8) | 75.8 (71.8 to 79.5) |
| PPAS1: Serogroup C: >=1:4: Day 0 before dose 1 | 14.3 (11.4 to 17.6) | 14.9 (11.9 to 18.3) |
| PPAS1: Serogroup C: >=1:8: Day 0 before dose 1 | 5.2 (3.5 to 7.5) | 5.2 (3.5 to 7.5) |
| PPAS1: Serogroup C: >=1:4: Day 30 post dose 2 | 99.0 (97.7 to 99.7) | 96.4 (94.4 to 97.8) |
| PPAS1: Serogroup C: >=1:8: Day 30 post dose 2 | 98.8 (97.5 to 99.6) | 91.9 (89.3 to 94.1) |
| PPAS1: Serogroup W: >=1:4: Day 0 before dose 1 | 11.7 (9.1 to 14.8) | 11.0 (8.4 to 14.0) |
| PPAS1: Serogroup W: >=1:8: Day 0 before dose 1 | 3.7 (2.2 to 5.6) | 3.5 (2.1 to 5.4) |
| PPAS1: Serogroup W: >=1:4: Day 30 post dose 2 | 98.6 (97.2 to 99.5) | 98.3 (96.8 to 99.2) |
| PPAS1: Serogroup W: >=1:8: Day 30 post dose 2 | 96.5 (94.6 to 97.9) | 94.5 (92.1 to 96.3) |
| PPAS1: Serogroup Y: >=1:4: Day 0 before dose 1 | 10.0 (7.6 to 12.9) | 9.8 (7.4 to 12.7) |
| PPAS1: Serogroup Y: >=1:8: Day 0 before dose 1 | 6.4 (4.4 to 8.8) | 5.6 (3.8 to 7.9) |
| PPAS1: Serogroup Y: >=1:4: Day 30 post dose 2 | 98.3 (96.7 to 99.2) | 97.3 (95.5 to 98.5) |
| PPAS1: Serogroup Y: >=1:8: Day 30 post dose 2 | 96.5 (94.5 to 97.9) | 93.5 (91.0 to 95.5) |
| PPAS2: Serogroup A: >=1:4: Day 0 before dose 3 | 69.1 (65.0 to 73.0) | 73.7 (69.9 to 77.3) |
| PPAS2: Serogroup A: >=1:8: Day 0 before dose 3 | 33.7 (29.7 to 37.9) | 46.2 (42.0 to 50.4) |
| PPAS2: Serogroup A: >=1:4: Day 30 post dose 3 | 98.2 (96.6 to 99.1) | 98.1 (96.6 to 99.0) |
| PPAS2: Serogroup A: >=1:8: Day 30 post dose 3 | 94.7 (92.4 to 96.4) | 96.5 (94.6 to 97.8) |
| PPAS2: Serogroup C: >=1:4: Day 0 before dose 3 | 92.5 (89.9 to 94.5) | 62.1 (57.9 to 66.1) |
| PPAS2: Serogroup C: >=1:8: Day 0 before dose 3 | 88.1 (85.1 to 90.7) | 41.6 (37.5 to 45.8) |
| PPAS2: Serogroup C: >=1:4: Day 30 post dose 3 | 99.8 (99.0 to 100) | 98.1 (96.6 to 99.0) |
| PPAS2: Serogroup C: >=1:8: Day 30 post dose 3 | 99.6 (98.7 to 100) | 95.5 (93.5 to 97.0) |
| PPAS2: Serogroup W: >=1:4: Day 0 before dose 3 | 96.7 (94.8 to 98.0) | 91.2 (88.5 to 93.4) |
| PPAS2: Serogroup W: >=1:8: Day 0 before dose 3 | 89.1 (86.2 to 91.6) | 77.6 (73.9 to 81.0) |
| PPAS2: Serogroup W: >=1:4: Day 30 post dose 3 | 100 (99.3 to 100) | 100 (99.4 to 100) |
| PPAS2: Serogroup W: >=1:8: Day 30 post dose 3 | 99.8 (99.0 to 100) | 99.5 (98.5 to 99.9) |
| PPAS2: Serogroup Y: >=1:4: Day 0 before dose 3 | 95.8 (93.7 to 97.3) | 85.7 (82.5 to 88.4) |
| PPAS2: Serogroup Y: >=1:8: Day 0 before dose 3 | 87.9 (84.9 to 90.5) | 69.6 (65.6 to 73.3) |
| PPAS2: Serogroup Y: >=1:4: Day 30 post dose 3 | 100 (99.3 to 100) | 100 (99.4 to 100) |
| PPAS2: Serogroup Y: >=1:8: Day 30 post dose 3 | 100 (99.3 to 100) | 99.8 (99.0 to 100) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|
| PPAS1: Serogroup A: >=1:4: Day 0 before dose 1 | 33.0 (23.6 to 43.4) | 32.6 (23.0 to 43.3) |
| PPAS1: Serogroup A: >=1:8: Day 0 before dose 1 | 14.9 (8.4 to 23.7) | 11.2 (5.5 to 19.7) |
| PPAS1: Serogroup A: >=1:4: Day 30 post dose 2 | 79.1 (69.3 to 86.9) | — |
| PPAS1: Serogroup A: >=1:8: Day 30 post dose 2 | 63.7 (53.0 to 73.6) | — |
| PPAS1: Serogroup A: >=1:4: Day 30 post dose 3 | — | 92.0 (84.3 to 96.7) |
| PPAS1: Serogroup A: >=1:8: Day 30 post dose 3 | — | 81.8 (72.2 to 89.2) |
| PPAS1: Serogroup C: >=1:4: Day 0 before dose 1 | 43.6 (33.4 to 54.2) | 48.9 (38.2 to 59.7) |
| PPAS1: Serogroup C: >=1:8: Day 0 before dose 1 | 26.6 (18.0 to 36.7) | 32.2 (22.8 to 42.9) |
| PPAS1: Serogroup C: >=1:4: Day 30 post dose 2 | 98.9 (94.3 to 100) | — |
| PPAS1: Serogroup C: >=1:8: Day 30 post dose 2 | 98.9 (94.3 to 100) | — |
| PPAS1: Serogroup C: >=1:4: Day 30 post dose 3 | — | 98.9 (94.0 to 100) |
| PPAS1: Serogroup C: >=1:8: Day 30 post dose 3 | — | 98.9 (94.0 to 100) |
| PPAS1: Serogroup W: >=1:4: Day 0 before dose 1 | 28.7 (19.9 to 39.0) | 35.6 (25.7 to 46.3) |
| PPAS1: Serogroup W: >=1:8: Day 0 before dose 1 | 10.6 (5.2 to 18.7) | 16.7 (9.6 to 26.0) |
| PPAS1: Serogroup W: >=1:4: Day 30 post dose 2 | 99.0 (94.3 to 100) | — |
| PPAS1: Serogroup W: >=1:8: Day 30 post dose 2 | 96.9 (91.1 to 99.4) | — |
| PPAS1: Serogroup W: >=1:4: Day 30 post dose 3 | — | 98.9 (94.0 to 100) |
| PPAS1: Serogroup W: >=1:8: Day 30 post dose 3 | — | 98.9 (94.0 to 100) |
| PPAS1: Serogroup Y: >=1:4: Day 0 before dose 1 | 26.6 (18.0 to 36.7) | 22.2 (14.1 to 32.2) |
| PPAS1: Serogroup Y: >=1:8: Day 0 before dose 1 | 12.8 (6.8 to 21.2) | 12.2 (6.3 to 20.8) |
| PPAS1: Serogroup Y: >=1:4: Day 30 post dose 2 | 99.0 (94.3 to 100) | — |
| PPAS1: Serogroup Y: >=1:8: Day 30 post dose 2 | 95.8 (89.7 to 98.9) | — |
| PPAS1: Serogroup Y: >=1:4: Day 30 post dose 3 | — | 98.9 (94.0 to 100) |
| PPAS1: Serogroup Y: >=1:8: Day 30 post dose 3 | — | 98.9 (94.0 to 100) |
| PPAS2: Serogroup A: >=1:4: Day 0 before dose 3 | 65.9 (55.3 to 75.5) | — |
| PPAS2: Serogroup A: >=1:8: Day 0 before dose 3 | 37.4 (27.4 to 48.1) | — |
| PPAS2: Serogroup A: >=1:4: Day 30 post dose 3 | 92.4 (84.9 to 96.9) | — |
| PPAS2: Serogroup A: >=1:8: Day 30 post dose 3 | 89.1 (80.9 to 94.7) | — |
| PPAS2: Serogroup A: >=1:4: Day 0 before dose 4 | — | 80.9 (71.2 to 88.5) |
| PPAS2: Serogroup A: >=1:8: Day 0 before dose 4 | — | 52.8 (41.9 to 63.5) |
| PPAS2: Serogroup A: >=1:4: Day 30 post dose 4 | — | 82.0 (72.5 to 89.4) |
| PPAS2: Serogroup A: >=1:8: Day 30 post dose 4 | — | 82.0 (72.5 to 89.4) |
| PPAS2: Serogroup C: >=1:4: Day 0 before dose 3 | 87.2 (78.8 to 93.2) | — |
| PPAS2: Serogroup C: >=1:8: Day 0 before dose 3 | 79.8 (70.2 to 87.4) | — |
| PPAS2: Serogroup C: >=1:4: Day 30 post dose 3 | 100 (96.1 to 100) | — |
| PPAS2: Serogroup C: >=1:8: Day 30 post dose 3 | 100 (96.1 to 100) | — |
| PPAS2: Serogroup C: >=1:4: Day 0 before dose 4 | — | 97.8 (92.1 to 99.7) |
| PPAS2: Serogroup C: >=1:8: Day 0 before dose 4 | — | 92.1 (84.5 to 96.8) |
| PPAS2: Serogroup C: >=1:4: Day 30 post dose 4 | — | 100 (95.8 to 100) |
| PPAS2: Serogroup C: >=1:8: Day 30 post dose 4 | — | 100 (95.8 to 100) |
| PPAS2: Serogroup W: >=1:4: Day 0 before dose 3 | 96.8 (90.9 to 99.3) | — |
| PPAS2: Serogroup W: >=1:8: Day 0 before dose 3 | 92.5 (85.1 to 96.9) | — |
| PPAS2: Serogroup W: >=1:4: Day 30 post dose 3 | 100 (95.8 to 100) | — |
| PPAS2: Serogroup W: >=1:8: Day 30 post dose 3 | 100 (95.8 to 100) | — |
| PPAS2: Serogroup W: >=1:4: Day 0 before dose 4 | — | 100 (96.0 to 100) |
| PPAS2: Serogroup W: >=1:8: Day 0 before dose 4 | — | 100 (96.0 to 100) |
| PPAS2: Serogroup W: >=1:4: Day 30 post dose 4 | — | 100 (95.8 to 100) |
| PPAS2: Serogroup W: >=1:8: Day 30 post dose 4 | — | 100 (95.8 to 100) |
| PPAS2: Serogroup Y: >=1:4: Day 0 before dose 3 | 94.7 (88.0 to 98.3) | — |
| PPAS2: Serogroup Y: >=1:8: Day 0 before dose 3 | 89.4 (81.3 to 94.8) | — |
| PPAS2: Serogroup Y: >=1:4: Day 30 post dose 3 | 100 (96.2 to 100) | — |
| PPAS2: Serogroup Y: >=1:8: Day 30 post dose 3 | 100 (96.2 to 100) | — |
| PPAS2: Serogroup Y: >=1:4: Day 0 before dose 4 | — | 100 (96.0 to 100) |
| PPAS2: Serogroup Y: >=1:8: Day 0 before dose 4 | — | 100 (96.0 to 100) |
| PPAS2: Serogroup Y: >=1:4: Day 30 post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup Y: >=1:8: Day 30 post dose 4 | — | 100 (95.9 to 100) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre vaccination titer \<1:8, the post-vaccination titer must be \>=1:16 and for a participant with a pre vaccination titer \>=1:8, the post-vaccination titer must be at least 4-fold greater than the pre vaccination titer. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix |
|---|---|---|
| PPAS1: Serogroup A: Day 30 post dose 2 | 46.7 (42.3 to 51.2) | 60.9 (56.5 to 65.2) |
| PPAS1: Serogroup C: Day 30 post dose 2 | 97.4 (95.7 to 98.6) | 86.8 (83.5 to 89.6) |
| PPAS1: Serogroup W: Day 30 post dose 2 | 92.6 (90.0 to 94.7) | 88.4 (85.4 to 91.1) |
| PPAS1: Serogroup Y: Day 30 post dose 2 | 87.1 (83.9 to 89.9) | 81.4 (77.8 to 84.7) |
| PPAS2: Serogroup A: Day 30 post dose 3 | 90.6 (87.8 to 92.9) | 91.7 (89.1 to 93.8) |
| PPAS2: Serogroup C: Day 30 post dose 3 | 98.7 (97.4 to 99.5) | 91.3 (88.7 to 93.5) |
| PPAS2: Serogroup W: Day 30 post dose 3 | 99.4 (98.4 to 99.9) | 98.4 (97.0 to 99.3) |
| PPAS2: Serogroup Y: Day 30 post dose 3 | 98.7 (97.4 to 99.5) | 96.9 (95.1 to 98.1) |
Functional meningococcal antibody activity against serogroups A, C, W, and Y were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse was defined for a participant with a pre vaccination titer \<1:8, the post-vaccination titer must be \>=1:16 and for a participant with a pre vaccination titer \>=1:8, the post-vaccination titer must be at least 4-fold greater than the pre vaccination titer. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|
| PPAS1: Serogroup A: Day 30 post dose 2 | 51.7 (40.8 to 62.4) | — |
| PPAS1: Serogroup A: Day 30 post dose 3 | — | 65.5 (54.6 to 75.4) |
| PPAS1: Serogroup C: Day 30 post dose 2 | 92.5 (85.1 to 96.9) | — |
| PPAS1: Serogroup C: Day 30 post dose 3 | — | 96.7 (90.6 to 99.3) |
| PPAS1: Serogroup W: Day 30 post dose 2 | 94.7 (88.0 to 98.3) | — |
| PPAS1: Serogroup W: Day 30 post dose 3 | — | 95.6 (89.0 to 98.8) |
| PPAS1: Serogroup Y: Day 30 post dose 2 | 89.4 (81.3 to 94.8) | — |
| PPAS1: Serogroup Y: Day 30 post dose 3 | — | 94.4 (87.5 to 98.2) |
| PPAS2: Serogroup A: Day 30 post dose 3 | 77.8 (67.8 to 85.9) | — |
| PPAS2: Serogroup A: Day 30 post dose 4 | — | 63.6 (52.7 to 73.6) |
| PPAS2: Serogroup C: Day 30 post dose 3 | 97.8 (92.4 to 99.7) | — |
| PPAS2: Serogroup C: Day 30 post dose 4 | — | 95.3 (88.5 to 98.7) |
| PPAS2: Serogroup W: Day 30 post dose 3 | 97.7 (91.9 to 99.7) | — |
| PPAS2: Serogroup W: Day 30 post dose 4 | — | 89.5 (81.1 to 95.1) |
| PPAS2: Serogroup Y: Day 30 post dose 3 | 91.5 (83.9 to 96.3) | — |
| PPAS2: Serogroup Y: Day 30 post dose 4 | — | 80.9 (71.2 to 88.5) |
GMCs of anti-pertussis antibodies (pertussis toxin \[PT\], filamentous hemagglutinin \[FHA\]) were measured by electrochemiluminescent (ECL) assay.
| Titer | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| PPAS1: Anti-PT: Day 0 before dose 1 | 2.97 (2.68 to 3.29) | 2.61 (2.38 to 2.87) | 11.0 (8.74 to 14.0) | — |
| PPAS1: Anti-FHA: Day 0 before dose 1 | 10.8 (9.73 to 12.1) | 10.1 (9.10 to 11.2) | 55.6 (42.4 to 73.0) | — |
| PPAS2: Anti-PT: Day 0 before dose 4 | — | — | — | 10.7 (8.82 to 13.1) |
| PPAS2: Anti-FHA: Day 0 before dose 4 | — | — | — | 30.3 (25.0 to 36.7) |
GMCs of hexavalent vaccines were measured as: anti-diphtheria, anti-tetanus, anti-pertussis antibodies (PT, FHA) by ECL assay, anti-hepatitis antibodies (anti-Hepatitis B surface antigen \[HBsAg\]) by the commercially available VITROS ECi/ECiQ, anti-poliovirus types 1, 2, and 3 by neutralization assay and anti-Haemophilus influenzae type b (anti-polyribosylribitol phosphate \[PRP\]) by Farr-type radioimmunoassay (RIA).
| Titer | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| PPAS1: Anti-diphtheria: Day 30 after dose 2 | 0.523 (0.474 to 0.578) | 0.489 (0.443 to 0.541) | 0.563 (0.458 to 0.691) | — |
| PPAS1: Anti-tetanus: Day 30 after dose 2 | 1.10 (1.02 to 1.18) | 1.13 (1.05 to 1.22) | 0.931 (0.788 to 1.10) | — |
| PPAS1: Anti-PT: Day 30 after dose 2 | 64.9 (61.4 to 68.7) | 68.1 (64.5 to 72.0) | 50.0 (43.2 to 58.0) | — |
| PPAS1: Anti-FHA: Day 30 after dose 2 | 92.4 (87.3 to 97.8) | 96.6 (90.8 to 103) | 125 (109 to 144) | — |
| PPAS1: Anti-HBsAg: Day 30 after dose 2 | 369 (323 to 421) | 345 (303 to 393) | 218 (147 to 322) | — |
| PPAS1: Anti-polio 1: Day 30 after dose 2 | 47.1 (40.1 to 55.3) | 43.5 (37.0 to 51.2) | 362 (260 to 504) | — |
| PPAS1: Anti-polio 2: Day 30 after dose 2 | 139 (117 to 167) | 143 (120 to 171) | 618 (429 to 890) | — |
| PPAS1: Anti-polio 3: Day 30 after dose 2 | 133 (112 to 157) | 145 (123 to 172) | 584 (419 to 814) | — |
| PPAS1: Anti-PRP: Day 30 after dose 2 | 0.376 (0.326 to 0.435) | 0.435 (0.379 to 0.499) | 0.725 (0.492 to 1.07) | — |
| PPAS2: Anti-diphtheria: Day 0 before dose 3 | 0.086 (0.079 to 0.095) | 0.080 (0.073 to 0.087) | 0.094 (0.076 to 0.116) | — |
| PPAS2: Anti-diphtheria: Day 30 after dose 3 | 1.82 (1.69 to 1.96) | 1.69 (1.57 to 1.81) | 2.71 (2.36 to 3.11) | — |
| PPAS2: Anti-diphtheria: Day 30 after dose 4 | — | — | — | 3.26 (2.88 to 3.69) |
| PPAS2: Anti-tetanus: Day 0 before dose 3 | 0.362 (0.336 to 0.391) | 0.424 (0.397 to 0.453) | 0.218 (0.180 to 0.264) | — |
| PPAS2: Anti-tetanus: Day 30 after dose 3 | 6.71 (6.33 to 7.12) | 8.59 (8.13 to 9.08) | 6.02 (5.06 to 7.16) | — |
| PPAS2: Anti-tetanus: Day 30 after dose 4 | — | — | — | 7.00 (5.99 to 8.18) |
| PPAS2: Anti-PT: Day 0 before dose 3 | 14.8 (13.8 to 15.8) | 14.6 (13.7 to 15.6) | 10.4 (8.99 to 12.0) | — |
| PPAS2: Anti-PT: Day 30 after dose 3 | 111 (105 to 118) | 109 (104 to 115) | 79.2 (66.2 to 94.6) | — |
| PPAS2: Anti-PT: Day 30 after dose 4 | — | — | — | 80.9 (68.2 to 95.9) |
| PPAS2: Anti-FHA: Day 0 before dose 3 | 38.4 (35.8 to 41.2) | 38.1 (35.5 to 40.8) | 30.6 (26.0 to 36.0) | — |
| PPAS2: Anti-FHA: Day 30 after dose 3 | 177 (167 to 187) | 184 (173 to 195) | 168 (142 to 200) | — |
| PPAS2: Anti-FHA: Day 30 after dose 4 | — | — | — | 181 (151 to 217) |
| PPAS2: Anti-HBsAg: Day 0 before dose 3 | 53.0 (45.5 to 61.8) | 48.8 (42.1 to 56.5) | 26.0 (17.6 to 38.2) | — |
| PPAS2: Anti-HBsAg: Day 30 after dose 3 | 2273 (1927 to 2681) | 2158 (1852 to 2515) | 1117 (666 to 1872) | — |
| PPAS2: Anti-HBsAg: Day 30 after dose 4 | — | — | — | 1144 (648 to 2020) |
| PPAS2: Anti-polio 1: Day 0 before dose 3 | 14.5 (12.7 to 16.5) | 13.6 (12.0 to 15.4) | 55.2 (40.8 to 74.6) | — |
| PPAS2: Anti-polio 1: Day 30 after dose 3 | 1099 (980 to 1233) | 994 (883 to 1119) | 1538 (1212 to 1952) | — |
| PPAS2: Anti-polio 1: Day 30 after dose 4 | — | — | — | 1625 (1291 to 2047) |
| PPAS2: Anti-polio 2: Day 0 before dose 3 | 33.2 (28.7 to 38.4) | 33.1 (28.8 to 37.9) | 85.3 (63.9 to 114) | — |
| PPAS2: Anti-polio 2: Day 30 after dose 3 | 2214 (1982 to 2472) | 2146 (1937 to 2379) | 3549 (2846 to 4425) | — |
| PPAS2: Anti-polio 2: Day 30 after dose 4 | — | — | — | 3858 (3001 to 4960) |
| PPAS2: Anti-polio 3: Day 0 before dose 3 | 19.7 (17.1 to 22.6) | 18.4 (16.0 to 21.1) | 37.7 (27.6 to 51.5) | — |
| PPAS2: Anti-polio 3: Day 30 after dose 3 | 1595 (1393 to 1827) | 1533 (1361 to 1728) | 2431 (1897 to 3115) | — |
| PPAS2: Anti-polio 3: Day 30 after dose 4 | — | — | — | 3397 (2567 to 4495) |
| PPAS2: Anti-PRP: Day 0 before dose 3 | 0.201 (0.176 to 0.230) | 0.224 (0.197 to 0.255) | 0.244 (0.174 to 0.343) | — |
| PPAS2: Anti-PRP: Day 30 after dose 3 | 9.42 (8.31 to 10.7) | 11.5 (10.3 to 12.9) | 16.1 (11.9 to 21.6) | — |
| PPAS2: Anti-PRP: Day 30 after dose 4 | — | — | — | 16.1 (12.1 to 21.6) |
GMCs of anti-diphtheria, anti-tetanus, anti-poliovirus types 1, 2, and 3, anti-haemophilus influenzae type b (anti-PRP) vaccines were measured as: anti-diphtheria, anti-tetanus by ECL assay, anti-poliovirus types 1, 2, and 3 by neutralization assay and anti-Haemophilus influenzae type b (anti-PRP) by Farr-type RIA. Response rate was defined as percentage of participants who achieved: anti diphtheria and anti-tetanus antibody concentrations \>=0.01 international units (IU)/milliliter (mL), \>=0.1 IU/mL and \>=1.0 IU/mL; anti-poliovirus types 1, 2, and 3 antibody titers \>=1:8; anti-PRP antibody concentrations \>=0.15 microgram (mcg)/mL and \>=1 mcg/mL. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| PPAS1: Anti-diphtheria: >=0.01 IU/mL: Day 30 post dose 2 | 100 (99.3 to 100) | 99.8 (98.9 to 100) | 100 (96.1 to 100) | — |
| PPAS1: Anti-diphtheria: >=0.1 IU/mL: Day 30 post dose 2 | 90.5 (87.6 to 92.9) | 89.6 (86.7 to 92.1) | 94.6 (87.9 to 98.2) | — |
| PPAS1: Anti-diphtheria: >=1.0 IU/mL: Day 30 post dose 2 | 32.7 (28.6 to 36.9) | 32.5 (28.5 to 36.7) | 33.3 (23.9 to 43.9) | — |
| PPAS1: Anti-tetanus: >=0.01 IU/mL: Day 30 post dose 2 | 100 (99.3 to 100) | 100 (99.3 to 100) | 100 (96.1 to 100) | — |
| PPAS1: Anti-tetanus: >=0.1 IU/mL: Day 30 post dose 2 | 100 (99.3 to 100) | 99.8 (98.9 to 100) | 100 (96.1 to 100) | — |
| PPAS1: Anti-tetanus: >=1.0 IU/mL: Day 30 post dose 2 | 53.3 (48.9 to 57.7) | 56.3 (52.0 to 60.7) | 44.1 (33.8 to 54.8) | — |
| PPAS1: Anti-polio 1: >=1:8: Day 30 post dose 2 | 87.0 (83.7 to 89.9) | 83.2 (79.6 to 86.4) | 98.8 (93.5 to 100) | — |
| PPAS1: Anti-polio 2:>=1:8: Day 30 post dose 2 | 97.5 (95.7 to 98.7) | 98.6 (97.0 to 99.4) | 100 (95.4 to 100) | — |
| PPAS1: Anti-polio 3:>=1:8: Day 30 post dose 2 | 95.9 (93.7 to 97.5) | 96.1 (94.0 to 97.7) | 98.8 (93.4 to 100) | — |
| PPAS1: Anti-PRP: >=0.15 mcg/mL: Day 30 post dose 2 | 71.8 (67.7 to 75.6) | 74.9 (70.9 to 78.5) | 78.1 (68.5 to 85.9) | — |
| PPAS1: Anti-PRP: >=1 mcg/mL: Day 30 post dose 2 | 24.2 (20.5 to 28.1) | 27.3 (23.5 to 31.3) | 39.6 (29.7 to 50.1) | — |
| PPAS2: Anti-diphtheria: >=0.01 IU/mL: Day 0 before dose 3 | 98.2 (96.6 to 99.1) | 98.6 (97.2 to 99.4) | 97.8 (92.3 to 99.7) | — |
| PPAS2: Anti-diphtheria: >=0.01 IU/mL: Day 30 after dose 3 | 100 (99.3 to 100) | 100 (99.4 to 100) | 100 (96.1 to 100) | — |
| PPAS2: Anti-diphtheria: >=0.01 IU/mL: Day 30 after dose 4 | — | — | — | 100 (95.9 to 100) |
| PPAS2: Anti-diphtheria: >=0.1 IU/mL: Day 0 before dose 3 | 48.2 (43.9 to 52.5) | 41.3 (37.2 to 45.5) | 47.3 (36.7 to 58.0) | — |
| PPAS2: Anti-diphtheria: >=0.1 IU/mL: Day 30 after dose 3 | 99.6 (98.7 to 100) | 99.8 (99.0 to 100) | 100 (96.1 to 100) | — |
| PPAS2: Anti-diphtheria: >=0.1 IU/mL: Day 30 after dose 4 | — | — | — | 100 (95.9 to 100) |
| PPAS2: Anti-diphtheria: >=1.0 IU/mL: Day 0 before dose 3 | 1.1 (0.4 to 2.4) | 0.7 (0.2 to 1.8) | 0 (0 to 4.0) | — |
| PPAS2: Anti-diphtheria: >=1.0 IU/mL: Day 30 after dose 3 | 75.5 (71.7 to 79.0) | 72.4 (68.6 to 76.1) | 92.4 (84.9 to 96.9) | — |
| PPAS2: Anti-diphtheria: >=1.0 IU/mL: Day 30 after dose 4 | — | — | — | 100 (95.9 to 100) |
| PPAS2: Anti-tetanus: >=0.01 IU/mL: Day 0 before dose 3 | 100 (99.3 to 100) | 100 (99.4 to 100) | 100 (96.1 to 100) | — |
| PPAS2: Anti-tetanus: >=0.01 IU/mL: Day 30 after dose 3 | 100 (99.3 to 100) | 100 (99.4 to 100) | 100 (96.1 to 100) | — |
| PPAS2: Anti-tetanus: >=0.01 IU/mL: Day 30 after dose 4 | — | — | — | 100 (95.9 to 100) |
| PPAS2: Anti- tetanus: >=0.1 IU/mL: Day 0 before dose 3 | 94.1 (91.8 to 95.9) | 97.4 (95.7 to 98.5) | 83.7 (74.5 to 90.6) | — |
| PPAS2: Anti-tetanus: >=0.1 IU/mL: Day 30 after dose 3 | 100 (99.3 to 100) | 100 (99.4 to 100) | 100 (96.1 to 100) | — |
| PPAS2: Anti-tetanus: >=0.1 IU/mL: Day 30 after dose 4 | — | — | — | 100 (95.9 to 100) |
| PPAS2: Anti-tetanus: >=1.0 IU/mL: Day 0 before dose 3 | 10.7 (8.2 to 13.6) | 14.7 (11.9 to 17.9) | 6.5 (2.4 to 13.7) | — |
| PPAS2: Anti-tetanus: >=1.0 IU/mL: Day 30 after dose 3 | 99.6 (98.7 to 100) | 99.7 (98.8 to 100) | 96.7 (90.8 to 99.3) | — |
| PPAS2: Anti-tetanus: >=1.0 IU/mL: Day 30 after dose 4 | — | — | — | 98.9 (93.9 to 100) |
| PPAS2: Anti-polio 1: >=1:8: Day 0 before dose 3 | 64.4 (60.2 to 68.5) | 63.7 (59.5 to 67.7) | 93.3 (85.9 to 97.5) | — |
| PPAS2: Anti-polio 1: >=1:8: Day 30 after dose 3 | 99.8 (99.0 to 100) | 98.9 (97.7 to 99.6) | 100 (95.8 to 100) | — |
| PPAS2: Anti-polio 1: >=1:8: Day 30 after dose 4 | — | — | — | 100 (95.8 to 100) |
| PPAS2: Anti-polio 2: >=1:8: Day 0 before dose 3 | 79.5 (75.8 to 82.9) | 80.9 (77.4 to 84.1) | 95.5 (88.8 to 98.7) | — |
| PPAS2: Anti-polio 2: >=1:8: Day 30 after dose 3 | 100 (99.3 to 100) | 100 (99.3 to 100) | 100 (95.8 to 100) | — |
| PPAS2: Anti-polio 2: >=1:8: Day 30 after dose 4 | — | — | — | 100 (95.8 to 100) |
| PPAS2: Anti-polio 3: >=1:8: Day 0 before dose 3 | 68.6 (64.5 to 72.6) | 65.7 (61.6 to 69.6) | 84.3 (75.0 to 91.1) | — |
| PPAS2: Anti-polio 3: >=1:8: Day 30 after dose 3 | 99.2 (98.1 to 99.8) | 99.8 (99.0 to 100) | 100 (95.8 to 100) | — |
| PPAS2: Anti-polio 3: >=1:8: Day 30 after dose 4 | — | — | — | 100 (95.8 to 100) |
| PPAS2: Anti-PRP: >=0.15 mcg/mL: Day 0 before dose 3 | 56.5 (52.2 to 60.7) | 60.4 (56.3 to 64.5) | 60.2 (49.5 to 70.2) | — |
| PPAS2: Anti-PRP: >=0.15 mcg/mL: Day 30 after dose 3 | 98.2 (96.7 to 99.1) | 98.8 (97.5 to 99.5) | 100 (96.0 to 100) | — |
| PPAS2: Anti-PRP: >=0.15 mcg/mL: Day 30 after dose 4 | — | — | — | 100 (96.0 to 100) |
| PPAS2: Anti-PRP: >=1 mcg/mL: Day 0 before dose 3 | 13.9 (11.1 to 17.1) | 14.9 (12.1 to 18.1) | 15.1 (8.5 to 24.0) | — |
| PPAS2: Anti-PRP: >=1 mcg/mL: Day 30 after dose 3 | 91.5 (88.9 to 93.7) | 94.9 (92.7 to 96.5) | 97.8 (92.3 to 99.7) | — |
| PPAS2: Anti-PRP: >=1 mcg/mL: Day 30 after dose 4 | — | — | — | 96.7 (90.6 to 99.3) |
GMCs of anti-pertussis antibodies (PT, FHA) were measured by ECL assay. The pertussis vaccine seroresponse for anti-PT and anti-FHA was defined as: For groups 1, 2, and 3, 30 days after dose 2 in infancy as if the pre-primary vaccination concentration is \<4 × lower limit of quantification (LLOQ), post-primary vaccination concentration \>=4 × LLOQ, if the pre-primary vaccination concentration is \>=4 ×LLOQ, post-primary vaccination concentration \>=pre-primary vaccination concentration; and for Groups 1, 2, and 3, before and 30 days after the dose 3 and for group 4, before and 30 days after the dose 4 as if the pre-booster vaccination concentration is \<4 × LLOQ, post-booster vaccination concentration \>=4 × pre-booster concentration, if the pre-booster vaccination concentration is \>=4 × LLOQ, post-booster vaccination concentration \>=2 × pre-booster concentration. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| PPAS1: Anti-PT: Day 30 post dose 2 | 94.5 (92.2 to 96.3) | 97.9 (96.2 to 98.9) | 82.6 (73.3 to 89.7) | — |
| PPAS1: Anti-FHA: Day 30 post dose 2 | 89.6 (86.7 to 92.1) | 91.5 (88.8 to 93.8) | 62.0 (51.2 to 71.9) | — |
| PPAS2: Anti-PT: Day 30 post dose 3 | 97.0 (95.2 to 98.3) | 97.0 (95.2 to 98.2) | 93.3 (86.1 to 97.5) | — |
| PPAS2: Anti-PT: Day 30 post dose 4 | — | — | — | 88.8 (80.3 to 94.5) |
| PPAS2: Anti-FHA: Day 30 post dose 3 | 89.1 (86.2 to 91.6) | 90.1 (87.3 to 92.4) | 92.2 (84.6 to 96.8) | — |
| PPAS2: Anti-FHA: Day 30 post dose 4 | — | — | — | 91.0 (83.1 to 96.0) |
GMCs of anti-hepatitis antibodies (anti-HBsAg) was measured by the commercially available VITROS ECi/ECiQ. Response rate for anti-HBsAg was defined as percentage of participants who achieved anti-HBsAg antibody concentrations \>=10 mIU/mL and \>=100 mIU/mL. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| PPAS1: Anti-HBsAg: >=10 mIU/mL: Day 30 post dose 2 | 96.4 (94.4 to 97.9) | 97.8 (96.2 to 98.9) | 92.4 (84.9 to 96.9) | — |
| PPAS1: Anti-HBsAg: >=100 mIU/mL: Day 30 post dose 2 | 85.7 (82.4 to 88.7) | 81.8 (78.1 to 85.0) | 72.8 (62.6 to 81.6) | — |
| PPAS2: Anti-HBsAg: >=10 mIU/mL: Day 0 before dose 3 | 81.5 (77.9 to 84.7) | 79.5 (75.9 to 82.7) | 65.9 (55.3 to 75.5) | — |
| PPAS2: Anti-HBsAg: >=10 mIU/mL: Day 30 after dose 3 | 98.0 (96.4 to 99.0) | 98.6 (97.3 to 99.4) | 94.4 (87.5 to 98.2) | — |
| PPAS2: Anti-HBsAg: >=10 mIU/mL: Day 0 before dose 4 | — | — | — | 64.4 (53.7 to 74.3) |
| PPAS2: Anti-HBsAg: >=10 mIU/mL: Day 30 after dose 4 | — | — | — | 91.9 (83.9 to 96.7) |
| PPAS2: Anti-HBsAg: >=100 mIU/mL: Day 0 before dose 3 | 38.7 (34.5 to 43.0) | 35.4 (31.5 to 39.5) | 26.4 (17.7 to 36.7) | — |
| PPAS2: Anti-HBsAg: >=100 mIU/mL: Day 30 after dose 3 | 93.4 (91.0 to 95.3) | 93.5 (91.2 to 95.4) | 80.0 (70.2 to 87.7) | — |
| PPAS2: Anti-HBsAg: >=100 mIU/mL: Day 0 before dose 4 | — | — | — | 27.8 (18.9 to 38.2) |
| PPAS2: Anti-HBsAg: >=100 mIU/mL: Day 30 after dose 4 | — | — | — | 83.7 (74.2 to 90.8) |
GMCs of anti-pneumococcal antibodies was assessed by pneumococcal capsular polysaccharide (PnPS) Immunoglobulin G (IgG) ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) antibodies in human serum.
| Titer | Group 1: MenACYW | Group 2: Nimenrix |
|---|---|---|
| PPAS1: Serogroup 1 | 1.68 (1.52 to 1.84) | 1.71 (1.56 to 1.87) |
| PPAS1: Serogroup 4 | 1.97 (1.83 to 2.12) | 2.06 (1.91 to 2.23) |
| PPAS1: Serogroup 5 | 1.08 (0.991 to 1.17) | 1.10 (1.01 to 1.19) |
| PPAS1: Serogroup 6B | 0.600 (0.534 to 0.675) | 0.660 (0.586 to 0.742) |
| PPAS1: Serogroup 7F | 2.03 (1.89 to 2.17) | 2.20 (2.05 to 2.37) |
| PPAS1: Serogroup 9V | 1.67 (1.54 to 1.81) | 1.81 (1.67 to 1.96) |
| PPAS1: Serogroup 14 | 5.92 (5.41 to 6.48) | 5.97 (5.44 to 6.55) |
| PPAS1: Serogroup 18C | 0.680 (0.618 to 0.748) | 0.796 (0.722 to 0.879) |
| PPAS1: Serogroup 19F | 1.59 (1.39 to 1.82) | 1.45 (1.26 to 1.66) |
| PPAS1: Serogroup 23F | 0.830 (0.746 to 0.924) | 0.869 (0.785 to 0.961) |
| PPAS2: Serogroup 1 | 4.71 (4.32 to 5.13) | 4.54 (4.18 to 4.94) |
| PPAS2: Serogroup 4 | 3.61 (3.37 to 3.86) | 3.19 (2.99 to 3.41) |
| PPAS2: Serogroup 5 | 2.21 (2.05 to 2.39) | 2.05 (1.90 to 2.20) |
| PPAS2: Serogroup 6B | 4.21 (3.89 to 4.55) | 4.36 (4.04 to 4.71) |
| PPAS2: Serogroup 7F | 2.91 (2.73 to 3.10) | 2.89 (2.70 to 3.10) |
| PPAS2: Serogroup 9V | 4.08 (3.80 to 4.38) | 4.17 (3.89 to 4.47) |
| PPAS2: Serogroup 14 | 9.07 (8.44 to 9.75) | 7.89 (7.25 to 8.59) |
| PPAS2: Serogroup 18C | 2.12 (1.99 to 2.26) | 2.17 (2.03 to 2.33) |
| PPAS2: Serogroup 19F | 9.03 (8.32 to 9.81) | 8.41 (7.76 to 9.12) |
| PPAS2: Serogroup 23F | 2.24 (2.10 to 2.40) | 2.04 (1.90 to 2.18) |
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) antibodies in human serum.
| Titer | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|
| PPAS1: Serogroup 1: 30 days post dose 2 | 1.47 (1.16 to 1.87) | — |
| PPAS1: Serogroup 3: 30 days post dose 2 | 0.658 (0.554 to 0.781) | — |
| PPAS1: Serogroup 4: 30 days post dose 2 | 1.73 (1.42 to 2.12) | — |
| PPAS1: Serogroup 5: 30 days post dose 2 | 0.803 (0.617 to 1.04) | — |
| PPAS1: Serogroup 6A: 30 days post dose 2 | 1.65 (1.24 to 2.19) | — |
| PPAS1: Serogroup 6B: 30 days post dose 2 | 0.275 (0.205 to 0.368) | — |
| PPAS1: Serogroup 7F: 30 days post dose 2 | 3.04 (2.59 to 3.57) | — |
| PPAS1: Serogroup 9V: 30 days post dose 2 | 1.25 (0.987 to 1.59) | — |
| PPAS1: Serogroup 14: 30 days post dose 2 | 5.88 (4.31 to 8.01) | — |
| PPAS1: Serogroup 18C: 30 days post dose 2 | 1.65 (1.30 to 2.10) | — |
| PPAS1: Serogroup 19A: 30 days post dose 2 | 2.17 (1.67 to 2.80) | — |
| PPAS1: Serogroup 19F: 30 days post dose 2 | 5.73 (4.64 to 7.08) | — |
| PPAS1: Serogroup 23F: 30 days post dose 2 | 0.722 (0.552 to 0.945) | — |
| PPAS2: Serogroup 1: 30 days post dose 3 | 5.32 (4.41 to 6.42) | — |
| PPAS2: Serogroup 1: 30 days post dose 4 | — | 5.47 (4.66 to 6.42) |
| PPAS2: Serogroup 3: 30 days post dose 3 | 1.13 (0.945 to 1.35) | — |
| PPAS2: Serogroup 3: 30 days post dose 4 | — | 1.21 (0.982 to 1.50) |
| PPAS2: Serogroup 4: 30 days post dose 3 | 3.99 (3.43 to 4.64) | — |
| PPAS2: Serogroup 4: 30 days post dose 4 | — | 3.97 (3.35 to 4.70) |
| PPAS2: Serogroup 5: 30 days post dose 3 | 3.33 (2.75 to 4.03) | — |
| PPAS2: Serogroup 5: 30 days post dose 4 | — | 3.95 (3.36 to 4.65) |
| PPAS2: Serogroup 6A: 30 days post dose 3 | 12.9 (10.9 to 15.4) | — |
| PPAS2: Serogroup 6A: 30 days post dose 4 | — | 14.3 (12.2 to 16.8) |
| PPAS2: Serogroup 6B: 30 days post dose 3 | 7.01 (5.38 to 9.13) | — |
| PPAS2: Serogroup 6B: 30 days post dose 4 | — | 9.41 (7.86 to 11.3) |
| PPAS2: Serogroup 7F: 30 days post dose 3 | 5.36 (4.56 to 6.29) | — |
| PPAS2: Serogroup 7F: 30 days post dose 4 | — | 4.92 (4.20 to 5.76) |
| PPAS2: Serogroup 9V: 30 days post dose 3 | 5.12 (4.26 to 6.17) | — |
| PPAS2: Serogroup 9V: 30 days post dose 4 | — | 5.40 (4.65 to 6.26) |
| PPAS2: Serogroup 14: 30 days post dose 3 | 14.8 (12.2 to 18.1) | — |
| PPAS2: Serogroup 14: 30 days post dose 4 | — | 14.7 (12.1 to 17.9) |
| PPAS2: Serogroup 18C: 30 days post dose 3 | 3.18 (2.70 to 3.76) | — |
| PPAS2: Serogroup 18C: 30 days post dose 4 | — | 3.48 (3.00 to 4.03) |
| PPAS2: Serogroup 19A: 30 days post dose 3 | 8.82 (7.25 to 10.7) | — |
| PPAS2: Serogroup 19A: 30 days post dose 4 | — | 10.9 (9.26 to 12.9) |
| PPAS2: Serogroup 19F: 30 days post dose 3 | 12.1 (9.91 to 14.7) | — |
| PPAS2: Serogroup 19F: 30 days post dose 4 | — | 12.2 (10.5 to 14.2) |
| PPAS2: Serogroup 23F: 30 days post dose 3 | 3.70 (3.01 to 4.55) | — |
| PPAS2: Serogroup 23F: 30 days post dose 4 | — | 4.06 (3.45 to 4.76) |
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F) antibodies in human serum. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix |
|---|---|---|
| PPAS1: Serogroup 1 | 92.7 (90.0 to 94.8) | 93.6 (91.1 to 95.5) |
| PPAS1: Serogroup 4 | 96.8 (94.9 to 98.2) | 96.7 (94.7 to 98.1) |
| PPAS1: Serogroup 5 | 88.5 (85.4 to 91.2) | 90.6 (87.8 to 93.0) |
| PPAS1: Serogroup 6B | 67.1 (62.8 to 71.2) | 69.9 (65.7 to 73.8) |
| PPAS1: Serogroup 7F | 98.8 (97.4 to 99.6) | 98.2 (96.7 to 99.2) |
| PPAS1: Serogroup 9V | 94.6 (92.3 to 96.4) | 95.1 (92.9 to 96.8) |
| PPAS1: Serogroup 14 | 97.8 (96.1 to 98.9) | 98.2 (96.7 to 99.2) |
| PPAS1: Serogroup 18C | 72.5 (68.4 to 76.3) | 77.3 (73.5 to 80.9) |
| PPAS1: Serogroup 19F | 82.2 (78.6 to 85.4) | 79.3 (75.5 to 82.7) |
| PPAS1: Serogroup 23F | 77.8 (73.9 to 81.4) | 80.3 (76.6 to 83.6) |
| PPAS2: Serogroup 1 | 99.8 (99.0 to 100) | 99.8 (99.0 to 100) |
| PPAS2: Serogroup 4 | 99.8 (99.0 to 100) | 99.6 (98.7 to 100) |
| PPAS2: Serogroup 5 | 98.2 (96.6 to 99.1) | 97.7 (96.1 to 98.8) |
| PPAS2: Serogroup 6B | 98.9 (97.6 to 99.6) | 99.5 (98.5 to 99.9) |
| PPAS2: Serogroup 7F | 99.6 (98.7 to 100) | 99.3 (98.2 to 99.8) |
| PPAS2: Serogroup 9V | 99.8 (99.0 to 100) | 99.8 (99.0 to 100) |
| PPAS2: Serogroup 14 | 100 (99.3 to 100) | 99.3 (98.2 to 99.8) |
| PPAS2: Serogroup 18C | 99.1 (97.9 to 99.7) | 98.6 (97.2 to 99.4) |
| PPAS2: Serogroup 19F | 99.3 (98.1 to 99.8) | 99.3 (98.2 to 99.8) |
| PPAS2: Serogroup 23F | 98.5 (97.1 to 99.4) | 97.2 (95.5 to 98.4) |
GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which was used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) antibodies in human serum. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|
| PPAS1: Serogroup 1: 30 days post dose 2 | 89.9 (81.7 to 95.3) | — |
| PPAS1: Serogroup 3: 30 days post dose 2 | 82.0 (72.5 to 89.4) | — |
| PPAS1: Serogroup 4: 30 days post dose 2 | 96.6 (90.5 to 99.3) | — |
| PPAS1: Serogroup 5: 30 days post dose 2 | 76.4 (66.2 to 84.8) | — |
| PPAS1: Serogroup 6A: 30 days post dose 2 | 88.8 (80.3 to 94.5) | — |
| PPAS1: Serogroup 6B: 30 days post dose 2 | 40.4 (30.2 to 51.4) | — |
| PPAS1: Serogroup 7F: 30 days post dose 2 | 97.8 (92.1 to 99.7) | — |
| PPAS1: Serogroup 9V: 30 days post dose 2 | 88.8 (80.3 to 94.5) | — |
| PPAS1: Serogroup 14: 30 days post dose 2 | 96.6 (90.5 to 99.3) | — |
| PPAS1: Serogroup 18C: 30 days post dose 2 | 91.0 (83.1 to 96.0) | — |
| PPAS1: Serogroup 19A:30 days post dose 2 | 93.3 (85.9 to 97.5) | — |
| PPAS1: Serogroup 19F: 30 days post dose 2 | 98.9 (93.9 to 100) | — |
| PPAS1: Serogroup 23F: 30 days post dose 2 | 71.9 (61.4 to 80.9) | — |
| PPAS2: Serogroup 1: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 1: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 3: 30 days post dose 3 | 97.8 (92.3 to 99.7) | — |
| PPAS2: Serogroup 3: 30 days post dose 4 | — | 92.1 (84.5 to 96.8) |
| PPAS2: Serogroup 4: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 4: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 5: 30 days post dose 3 | 98.9 (94.0 to 100) | — |
| PPAS2: Serogroup 5: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 6A: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 6A: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 6B: 30 days post dose 3 | 98.9 (94.0 to 100) | — |
| PPAS2: Serogroup 6B: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 7F: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 7F: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 9V: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 9V: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 14: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 14: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 18C: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 18C: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 19A: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 19A: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 19F: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 19F: 30 days post dose 4 | — | 100 (95.9 to 100) |
| PPAS2: Serogroup 23F: 30 days post dose 3 | 100 (96.0 to 100) | — |
| PPAS2: Serogroup 23F: 30 days post dose 4 | — | 100 (95.9 to 100) |
GMCs of anti-measles and anti-rubella antibodies were measured by bulk IgG enzyme immunoassay (EIA) and anti-mumps antibodies were assessed by enzyme-linked immunosorbent assay (ELISA).
| Titer | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| Anti-measles: 30 days post dose 3 | 2780 (2581 to 2995) | 2919 (2739 to 3110) | 3457 (2972 to 4021) | — |
| Anti-measles: 30 days post dose 4 | — | — | — | 3933 (3241 to 4773) |
| Anti-mumps: 30 days post dose 3 | 83.3 (77.5 to 89.6) | 86.1 (80.5 to 92.1) | 105 (90.4 to 121) | — |
| Anti-mumps: 30 days post dose 4 | — | — | — | 121 (105 to 141) |
| Anti-rubella: 30 days post dose 3 | 56.8 (53.2 to 60.6) | 56.0 (52.5 to 59.8) | 72.8 (62.7 to 84.6) | — |
| Anti-rubella: 30 days post dose 4 | — | — | — | 74.4 (63.7 to 86.7) |
GMCs of anti-measles and anti-rubella antibodies were measured by bulk IgG EIA and anti-mumps antibodies were assessed by ELISA. Vaccine response against anti-measles, anti-mumps, anti-rubella antibodies were defined as percentage of participants with anti-measles, anti-mumps, anti-rubella antibody concentration that met the respective mentioned criterion: measles: \>=255 mIU/mL; mumps: \>=10 mumps antibody units/mL and rubella: \>=10 IU/mL. Percentages are rounded off to the tenth decimal place.
| Percentage of participants | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| Anti-measles: 30 days post dose 3 | 98.3 (96.8 to 99.2) | 99.1 (97.9 to 99.7) | 100 (96.2 to 100) | — |
| Anti-measles: 30 days post dose 4 | — | — | — | 97.8 (92.2 to 99.7) |
| Anti-mumps: 30 days post dose 3 | 98.7 (97.3 to 99.5) | 98.7 (97.4 to 99.5) | 100 (96.2 to 100) | — |
| Anti-mumps: 30 days post dose 4 | — | — | — | 100 (96.0 to 100) |
| Anti-rubella: 30 days post dose 3 | 98.7 (97.3 to 99.5) | 97.3 (95.6 to 98.5) | 98.9 (94.2 to 100) | — |
| Anti-rubella: 30 days post dose 4 | — | — | — | 100 (96.0 to 100) |
Collected over Adverse events (AEs), serious adverse events (SAEs) and all-cause mortality (deaths) were collected from the study vaccine administration (Day 0) until 30 days after the last vaccination (Visit 5 [13 to 19 MoA] for Groups 1, 2, and 3 and Visit 6 [13 to 19 MoA] for Group 4), up to 14 to 20 MoA.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MenACYW | 0/696 (0%) | 51/696 (7.3%) | 678/696 (97.4%) |
| Group 2: Nimenrix | 0/706 (0%) | 57/706 (8.1%) | 680/706 (96.3%) |
| Group 3: MenACYW | 0/112 (0%) | 8/112 (7.1%) | 107/112 (95.5%) |
| Group 4: MenACYW | 0/108 (0%) | 3/108 (2.8%) | 103/108 (95.4%) |
| Event | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/696 | 5/706 | 2/112 | 2/108 |
| Respiratory Syncytial Virus BronchiolitisInfections and infestations | 0/696 | 1/706 | 1/112 | 2/108 |
| BronchiolitisInfections and infestations | 2/696 | 2/706 | 2/112 | 0/108 |
| Lymphatic MalformationCongenital, familial and genetic disorders | 0/696 | 0/706 | 0/112 | 1/108 |
| Craniocerebral InjuryInjury, poisoning and procedural complications | 0/696 | 0/706 | 0/112 | 1/108 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/696 | 0/706 | 1/112 | 0/108 |
| Escherichia Urinary Tract InfectionInfections and infestations | 0/696 | 0/706 | 1/112 | 0/108 |
| Respiratory Syncytial Virus InfectionInfections and infestations | 1/696 | 0/706 | 1/112 | 0/108 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/696 | 0/706 | 1/112 | 0/108 |
| Clinically Isolated SyndromeNervous system disorders | 0/696 | 0/706 | 1/112 | 0/108 |
| Event | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW |
|---|---|---|---|---|
| IrritabilityPsychiatric disorders | 600/696 | 608/706 | 91/112 | 86/108 |
| CryingGeneral disorders | 579/696 | 579/706 | 74/112 | 75/108 |
| Injection Site PainGeneral disorders | 562/696 | 566/706 | 88/112 | 76/108 |
| SomnolenceNervous system disorders | 529/696 | 545/706 | 67/112 | 75/108 |
| Injection Site ErythemaGeneral disorders | 537/696 | 520/706 | 61/112 | 58/108 |
| Injection Site SwellingGeneral disorders | 422/696 | 417/706 | 41/112 | 47/108 |
| Decreased AppetiteMetabolism and nutrition disorders | 389/696 | 372/706 | 60/112 | 58/108 |
| PyrexiaGeneral disorders | 375/696 | 345/706 | 46/112 | 42/108 |
| VomitingGastrointestinal disorders | 196/696 | 197/706 | 25/112 | 27/108 |
| Respiratory Tract Infection ViralInfections and infestations | 0/696 | 1/706 | 18/112 | 22/108 |
All randomized participants included study participants for whom an injection group had been allocated.
| Age, Continuous(Days) | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW | Total |
|---|---|---|---|---|---|
| Mean | 72.6 ± 12.2 | 72.4 ± 12.1 | 62.5 ± 7.12 | 63.3 ± 7.93 | 71.2 ± 12.1 |
| Sex: Female, Male(Participants) | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW | Total |
|---|---|---|---|---|---|
| Female | 355 | 378 | 45 | 58 | 836 |
| Male | 359 | 348 | 67 | 50 | 824 |
| Race/Ethnicity, Customized(Participants) | Group 1: MenACYW | Group 2: Nimenrix | Group 3: MenACYW | Group 4: MenACYW | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 2 | 1 | 4 | 2 | 9 |
| Black or African American | 0 | 0 | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 1 |
| White | 693 | 699 | 106 | 101 | 1599 |
| Not Reported | 13 | 16 | 0 | 1 | 30 |
| Unknown | 2 | 3 | 0 | 0 | 5 |
| Multiple origin | 4 | 6 | 0 | 1 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2018 to primary completion in May 2023, 53 months.
Results were first posted in Jan 2025, 1 year 8 months after primary completion. A results delay was requested in Apr 2024.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 53 months is above that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →